← back to search

Ricardo Rojo

Pfizer (United States) · US
🔎 Find collaborators in Dermatology · Immunology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Dermatology · Immunology
Research interest
Research interests include Dermatology and Skin Diseases, Psoriasis: Treatment and Pathogenesis, Rheumatoid Arthritis Research and Therapies, and Allergic Rhinitis and Sensitization.
h-index
16
citations
2,475
works
67
NIH funding
primary concept
Medicine
email

Recent publications

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
New England Journal of Medicine 2021cited by 443position: middledoi
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis
JAMA Dermatology 2021cited by 158position: middledoi
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
American Journal of Clinical Dermatology 2021cited by 44position: middledoi
Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
Journal of the European Academy of Dermatology and Venereology 2021cited by 43position: middledoi
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet 2020cited by 477position: lastdoi
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
JAMA Dermatology 2020cited by 381position: lastdoi
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
Drug Safety 2020cited by 42position: lastdoi
Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
RMD Open 2019cited by 41position: middledoi
SAT0221 Efficacy and Safety of PF-04171327, a Novel Dissociated Agonist of the Glucocorticoid Receptor (DAGR): Results of a Phase 2, Randomized, Double-Blind Study
Annals of the Rheumatic Diseases 2015cited by 5position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hernán Valdez · Pfizer (United States)6 papers (2020–2021)Pinaki Biswas · Pfizer (United States)5 papers (2020–2021)Marco DiBonaventura · Pfizer (United States)5 papers (2020–2021)Claire Feeney · St. Mary’s Hospital5 papers (2020–2021)Jacob P. Thyssen · Steno Diabetes Centers4 papers (2020–2021)Eric L. Simpson · Eli Lilly (United States)4 papers (2020–2021)Jonathan I. Silverberg · Maimonides Medical Center3 papers (2020–2021)Gil Yosipovitch · University of Miami3 papers (2020–2021)Vibeke Strand · Stanford University2 papers (2015–2019)Thomas Bieber · CK-CARE2 papers (2020–2021)Rodney Sinclair · Melbourne Health2 papers (2020–2021)Carsten Flohr · King's College London2 papers (2020–2021)Frank Buttgereit · Humboldt-Universität zu Berlin2 papers (2015–2019) · 2 papers (2015–2019)Chia‐Yu Chu · National Taiwan Normal University2 papers (2021–2021) · 2 papers (2015–2019)Seth Forman · Skin Cancer Foundation2 papers (2020–2021)C. Paul · Centre National de la Recherche Scientifique2 papers (2021–2021) · 2 papers (2021–2021) · 2 papers (2020–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Dermatology · Immunology →